NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) a biotechnology company developing novel Listeria-based therapeutic cancer vaccines, noted the significance of a study conducted by the Centers for Disease Control and Prevention (CDC), that helps validate the treatable population of its Lovaxin C, cervical cancer vaccine currently in clinical trials.
